New York, NY – 01/01/2019. DermaClip® today announced the promotion of Dr. Jeffrey S. Freed, MD, FACS, FACG, to the position of Chief Medical Officer (CMO). Dr. Freed had previously held the position of Chairman of the DermaClip Medical Advisory Board.
"Dr. Freed has been a tremendous asset to DermaClip in the work he has done with Medical Advisory Board and we look forward to his increased involvement as Chief Medical Officer for this revolutionary non-invasive skin closure device," said DermaClip US CEO, Charles M. Darling IV.
Dr. Freed is an Associate Professor of Surgery at Mt. Sinai Hospital in New York City, the Branch Chief of Colorectal Surgery at the Bronx VA Hospital, and a dedicated an experienced and recognized clinician, and a dedicated humanitarian that frequently travels on missions to third-world countries to perform needed surgeries in underserved communities. In addition, he successfully founded a care company that went on to establish a national presence that was ultimately bought out by a major health company.
DermaClip® aims to optimize incision, laceration and wound repair through non-invasive, cost-effective and efficiency-producing skin closure devices. DermaClip is a non-invasive skin closure device that is an alternative to sutures, surgical staples and glues. The device aims to improve the patient experience while reducing the time and cost burden of closure by transforming a highly variable skill into a reproducible process. The device has been used in more than 30,000 cases, everywhere from in the field to the Emergency Department to the surgical suite. The DermaClip team believes that high quality skin closure should be available to everyone, regardless of access to high-end services. The team aims to eliminate the trade-offs in skin closure made between time of closure and quality of patient care. DermaClip is headquartered in Houston, TX. For more information, visit the DermaClip website. You can also find more about the DermaClip devices on Twitter, Facebook, LinkedIn, and Instagram.